Japan Central Nervous System Therapeutic Market Size & Outlook

The central nervous system therapeutic market in Japan is expected to reach a projected revenue of US$ 12,938.0 million by 2028. A compound annual growth rate of 6.8% is expected of Japan central nervous system therapeutic market from 2021 to 2028.
Revenue, 2020 (US$M)
$7,621.3
Forecast, 2028 (US$M)
$12,938.0
CAGR, 2021 - 2028
6.8%
Report Coverage
Japan

Japan central nervous system therapeutic market, 2018-2028 (US$M)

Japan

Japan central nervous system therapeutic market highlights

  • The Japan central nervous system therapeutic market generated a revenue of USD 7,621.3 million in 2020 and is expected to reach USD 12,938.0 million by 2028.
  • The Japan market is expected to grow at a CAGR of 6.8% from 2021 to 2028.
  • In terms of segment, mental health was the largest revenue generating disease in 2020.
  • Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.


Central nervous system therapeutic market data book summary

Market revenue in 2020USD 7,621.3 million
Market revenue in 2028USD 12,938.0 million
Growth rate6.8% (CAGR from 2020 to 2028)
Largest segmentMental health
Fastest growing segmentNeurodegenerative Diseases
Historical data2018 - 2019
Base year2020
Forecast period2021 - 2028
Quantitative unitsRevenue in USD million
Market segmentationNeurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
Key market players worldwideBiogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc


Other key industry trends

  • In terms of revenue, Japan accounted for 7.2% of the global central nervous system therapeutic market in 2020.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
  • In Asia Pacific, Japan central nervous system therapeutic market is projected to lead the regional market in terms of revenue in 2028.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,715.9 million by 2028.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Central Nervous System Therapeutic Market Companies

Name Profile # Employees HQ Website

Japan central nervous system therapeutic market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.


Mental health was the largest segment with a revenue share of 42.82% in 2020. Horizon Databook has segmented the Japan central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.


Japan is one the major markets for CNS therapeutics in the Asia Pacific region, which can be attributed to the presence of strong local players and well-established healthcare infrastructure. The Japanese government is responsible for the country’s Universal Statutory Health Insurance System (SHIS) fee schedule and provides financial benefits to insurers & service providers. 

In April 2018, Kyushu Certified Special Committee for Regenerative Medicine approved for the world’s first stem cell therapy, to treat mild-to-moderate Alzheimer’s disease. This innovative therapy has been developed by Korean biotech company Nature Cell and Biostar Stem Cell Research Institute. 

Approval of novel therapies and increasing R&D activities to develop effective treatment for neurological conditions are factors anticipated to drive the market over the forecast period. According to the Global Cancer Observatory, in 2020, the 5-year prevalence of brain.

Reasons to subscribe to Japan central nervous system therapeutic market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan central nervous system therapeutic market databook

  • Our clientele includes a mix of central nervous system therapeutic market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into Japan central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan central nervous system therapeutic market size, by disease, 2018-2028 (US$M)

Japan Central Nervous System Therapeutic Market Outlook Share, 2020 & 2028 (US$M)

Japan central nervous system therapeutic market size, by disease, 2018-2028 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more